Personalized Cancer Vaccine Candidate Reports Best-In-Class Results
Genocea Biosciences GEN-009 neoantigen vaccine candidate monotherapy elicited T cell responses to 91% of the vaccine neoantigens administered
A biopharmaceutical company developing personalized cancer immunotherapies announced best-in-class clinical results from its ongoing Phase 1/2a trial for GEN-009, a neoantigen vaccine candidate.
This GEN-009 announcement highlights the following results:
- In the 5 patients for whom immune response results are available to date, GEN-009 monotherapy elicited T cell responses to 91% of the vaccine neoantigens administered.
- GEN-009 has proven to be unique among neoantigen vaccines in its ability to elicit ex vivo CD8+ T cell responses, which were observed for 47% of vaccine neoantigens.
- Inclusive of the results seen after in vitro stimulation, the CD8+ T cell response frequency was 53%.
Roger B. Cohen, M.D., who is Associate Director Clinical Research at the Abramson Cancer Center, Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, and the principal investigator commented in a press release, “The Genocea data indicate that using the patients’ own T cells and antigen-presenting cells to select vaccine neoantigens results in higher immunogenicity than previously reported results using in silico methods.”
“I look forward to investigating GEN-009 in combination with checkpoint inhibitors to explore whether this higher immunogenicity translates into greater clinical efficacy than seen with other neoantigen vaccines,” said Dr. Cohen.
The GEN-009-101 Clinical Trial is a multicenter Phase 1/2a study being conducted in patients with melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and urothelial carcinoma.
In Part A of the clinical trial, enrolled patients had no evidence of disease at the time of vaccination and is expected to result in as many as 9 evaluable patients.
About Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies.